企業プロフィール
Theravance Biopharma 株価・ニュース・カタリスト
- ティッカー:
- TBPH
- 取引所:
- NASDAQ
- セクター:
- Biopharma
- 所在地:
- United States
株価パフォーマンス
16.92 USD (-0.29%)
終値
最終更新: 2026年8月17日
803M USD
時価総額
株価変動の要因
As of Aug 17, 2026, TBPH closed down 0.29% at $16.92. No new same-company headline was identified in the current news window.
企業概要
Respiratory Medicines
Theravance Biopharma is a biopharmaceutical company whose principal economic asset is a respiratory medicine commercialized through a collaboration.
YUPELRI
YUPELRI, or revefenacin, is a once-daily nebulized long-acting muscarinic antagonist for maintenance treatment of chronic obstructive pulmonary disease. Theravance receives collaboration revenue tied to U.S. sales. Following the outcome of the CYPRESS study, the company is winding down that clinical program and restructuring around its commercial asset and remaining strategic opportunities.
今後のカタリスト
最近のニュース
- 01
- 02
- 03
- 04
- 05
類似銘柄
事業成熟度、治療領域、カタリスト傾向が近い同業銘柄です。